Titan Medical loses clinical & regulatory EVP Fowler Titan Medical (CVE:TMD) said today that its executive vice president for clinical & regulatory affairs, Dr. Dennis Fowler, plans to resign effective August 31. Toronto-based robot-assisted surgery company Titan, which is grappling with the suspension of its product development program, said Fowler’s duties will be divided on an […]
Misonix
NASS 2015 Roundup: Spine trends stabilizing, new fields taking center stage
The spinal med device market appears to be stabilizing with growth in 3 key areas, according to a letter to investors published this week from Leerink Partner’s Richard Newitter, who attended the North American Spine Society’s annual meeting in Chicago last week. Newitter said the meeting was “neutral-to-positive” for firms in the spinal market, and said […]
Report: AdvaMed CEO Ubl to leave for top spot at PhHRMA | Personnel Moves
Steve Ubl, the longtime CEO at medical device lobby AdvaMed, is reportedly leaving the organization after 17 years to take the top spot at the pharmaceutical industry’s largest trade group, the Pharmaceutical Research and Manufacturers of America or PhRMA. The Hill, citing an unnamed source, said that Ubl “will more than likely” take over as […]
SEC dings Misonix investor relations exec for insider trading
Johnson and Johnson executive splits for the corner office at Itamar Medical | Personnel Moves
Surgical devices: Misonix swings to the red in Q2
Teleflex affirms 2012 guidance | Wall Street Beat
Teleflex (NYSE:TFX) said yesterday that it expects its 2012 earnings to meet Wall Street’s expectations, but forecast softer profits for the coming year.
The Limerick, Pa.-based medical device company said its "preliminary financial goals" for 2013 are for sales growth of 11%-13% and adjusted EPS of $4.70-$4.90.
Report: Blackstone leads race for Allscripts | Wall Street Beat
Blackstone Group is said to be leading the bidding war for electronic medical records company Allscripts (NSDQ:MDRX) but the 2 sides are far from agreeing on a price, according to Reuters.
Citing 3 "people familiar with the matter," the news agency said a deal is "highly uncertain."
NuVasive’s global sales president is on the way out | Personnel Moves
Misonix gains 19% on swing to black | Wall Street Beat
Misonix (NSDQ:MSON) shares are up 19% today after the medical device company swung to black ink for its fiscal 4th quarter and full year.
Farmingdale, N.Y.-based Misonix posted profits of $366,000, or 5¢ per share, on sales of $1.7 million for the 12 months ended June 30 – for a 26.7% top-line gain that helped Misonix swing from a $3.5 million loss during its last fiscal year.